1Odoul F, Leguellec C,Lamagnere JP,et al. Prediction of methotrexateelimination after high dose infusion in children with acute lymphoblastic leukemia using a population pharmacokinetic approach. Fundam Clin Parmacol, 1999, 13: 595-604.
2Rask C, Albert F, Bentzen SM, et al. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis.Acta Oncol,1998, 37: 277-284.
3Galpin AJ,Schuetz JD, Masson E, et al. Differences in folypolyglutamatate synthetase and dihydrofolate reductase expression in human Blineage versus T-lineage lymphoblastic leukemia: mechanisms for lineage difference in methotrexate polyglutamylation and cytotoxicity.Mol Pharmacol, 1997, 52: 155-163.
4Reni M,,Mazza E,Foppoli M,et al.Pri mary central nervous system lymphomas:Salvage treatment after failure to high-dose methotrex-ate[].Cancer Letters.2007
5Hempel L,Misselwitz J,Fleck C,et al.Influence of high-dose methotrexate therapy ( HD-MTX) on glomerular and tubular kidney function[].Medical and Pediatric Oncology.2003
